Terms: = Liver cancer AND NFE2L2, ENSG00000116044, 4780, Q16236, NRF2 AND Clinical Outcome
3 results:
1. Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse clinical outcome.
Li D; Yu T; Hu J; Wu J; Feng S; Xu Q; Zhu H; Zhang X; Zhang Y; Zhou B; Gu L; Zeng Z
Oxid Med Cell Longev; 2021; 2021():5175581. PubMed ID: 35003516
[TBL] [Abstract] [Full Text] [Related]
2. Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: cancer Metabolism and Immune Status.
Iseda N; Itoh S; Yoshizumi T; Tomiyama T; Morinaga A; Yugawa K; Shimokawa M; Shimagaki T; Wang H; Kurihara T; Kitamura Y; Nagao Y; Toshima T; Harada N; Kohashi K; Baba S; Ishigami K; Oda Y; Mori M
Hepatol Commun; 2022 Apr; 6(4):665-678. PubMed ID: 34687175
[TBL] [Abstract] [Full Text] [Related]
3. Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing nrf2 Activation.
Yu JI; Choi C; Shin SW; Son A; Lee GH; Kim SY; Park HC
Sci Rep; 2017 Nov; 7(1):14986. PubMed ID: 29118323
[TBL] [Abstract] [Full Text] [Related]
